Imunon, Inc. (Nasdaq: IMNN) presented updated clinical data for its IMNN-001 immunotherapy program at an R&D Day event, highlighting final ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE